NCHR Testimony on Omadacycline for Skin Infections and Pneumonia

August 8, 2018. If omadacycline is no better than some drugs on the market, and may be less safe or less effective for older patients, those with more serious infections, and patients with diabetes and lung disease, it is important to conduct further studies to know whether they should be excluded from the indication or not.

Read More »

NCHR Testimony of TIRF REMS

August 3, 2018. TIRFs provide important options for cancer patients dealing with pain. However, we all know that they carry very serious risks and that’s why we need REMS that protect patients’ these risks.  These REMS are not working as well as the should to protect patients and need to be approved.

Read More »
Page 1 of 3812345...102030...Last »